Research Article
[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer
Table 1
Baseline data of breast cancer patients with HER2-positive.
| | Items | Second-line () | Third-line () | Total () |
| | Age (years) | | | | | ECOG score [ (%)] | | | | | 0~1 | 16 (72.73) | 9 (69.23) | 25 (71.43) | | 2 | 6 (27.27) | 4 (30.77) | 10 (28.57) | | WHO grade [ (%)] | | | | | II | 15 (68.18) | 7 (53.85) | 22 (62.86) | | III | 7 (31.82) | 6 (46.15) | 13 (37.14) | | ER [positive, (%)] | 11 (50.00) | 6 (46.15) | 17 (48.57) | | PR [positive, (%)] | 13 (59.09) | 7 (53.85) | 20 (57.14) | | P53/P63 [positive, (%)] | 9 (40.91) | 4 (30.77) | 13 (37.14) | | Pathological type [ (%)] | | | | | Invasive carcinoma | 11 (50.00) | 6 (46.15) | 17 (48.57) | | Invasive ductal carcinoma | 6 (27.27) | 3 (23.08) | 9 (25.71) | | Other | 5 (22.73) | 4 (30.77) | 9 (25.71) | | Family history [yes, (%)] | 1 (4.55) | 1 (7.69) | 2 (5.71) | | Complications [yes, (%)] | 5 (22.73) | 2 (15.38) | 7 (20.00) | | Surgery [yes, (%)] | 15 (68.18) | 10 (76.92) | 25 (71.43) | | Vascular tumor thrombus [positive, (%)] | 8 (36.36) | 2 (15.38) | 10 (28.57) | | Combination chemotherapy [ (%)] | | | | | Capecitabine | 10 (45.45) | 4 (30.77) | 14 (40.00) | | Albumin paclitaxel | 6 (27.27) | 2 (15.38) | 8 (22.86) | | Gemcitabine | 2 (9.09) | 2 (15.38) | 4 (11.43) | | Other | 4 (18.18) | 5 (38.46) | 9 (25.71) |
|
|
